Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
Selling, General & Admin
5
5
4
7
5
4
Research & Development
5
4
4
5
6
6
Operating Expenses
10
9
8
13
12
11
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-10
-9
-8
-12
-12
-11
Income Tax Expense
--
0
0
0
0
0
Net Income
-10
-9
-8
-13
-12
-11
Net Income Growth
43%
13%
-38%
8%
9%
10%
Shares Outstanding (Diluted)
47.08
37.65
29
28.81
26.13
18.42
Shares Change (YoY)
25%
30%
1%
10%
42%
52%
EPS (Diluted)
-0.24
-0.25
-0.3
-0.45
-0.47
-0.61
EPS Growth
19%
-17%
-32%
-4%
-23%
-31%
Free Cash Flow
-7
-6
-7
-12
-9
-10
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
0%
0%
0%
0%
0%
0%
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-10
-9
-8
-13
-12
-11
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
-10
-9
-8
-13
-12
-11
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
0%
0%
0%
0%
0%
Follow-Up Questions
What are Entera Bio Ltd's key financial statements?
According to the latest financial statement (Form-10K), Entera Bio Ltd has a total asset of $9, Net loss of $-9
What are the key financial ratios for ENTX?
Entera Bio Ltd's Current ratio is 9, has a Net margin is 0, sales per share of $0.
How is Entera Bio Ltd's revenue broken down by segment or geography?
Entera Bio Ltd largest revenue segment is Oral Tablet Formats of Peptides, at a revenue of 181,000 in the most earnings release.For geography, Israel is the primary market for Entera Bio Ltd, at a revenue of 181,000.
Is Entera Bio Ltd profitable?
no, according to the latest financial statements, Entera Bio Ltd has a net loss of $-9
Does Entera Bio Ltd have any liabilities?
yes, Entera Bio Ltd has liability of 1
How many outstanding shares for Entera Bio Ltd?
Entera Bio Ltd has a total outstanding shares of 38.83